Breakthrough hantavirus vaccine in development by Moderna and Korea University

Moderna and Korea University have joined forces to develop a next‑generation hantavirus vaccine using mRNA technology.

hantavirus vaccine progress in pre‑clinical trials

Animal studies reported an immune response boost of ↑ 30% compared with earlier candidates, according to data cited by Reuters. The research team cautions that human trials are still pending, and regulatory pathways could add years to the timeline.

“We are optimistic but realistic about the path ahead,” said lead virologist Dr. Lee Min‑soo.

Industry analysts note that the collaboration reflects a broader shift toward mRNA platforms for zoonotic threats, a trend also highlighted by Bloomberg. Investors should temper expectations; the vaccine is unlikely to reach the market before ↓ 2029, if at all.